Back to results
US 11,141,389 B2Granted
Agents that inhibit NGLY1 and methods of use thereof
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorsCarolyn Ruth Bertozzi, Frederick Tomlin, Ulla Gerling-Driessen
Life of this patent
Estimating the term…
Abstract
Methods are provided for treatment of cancer cells, in a regimen comprising contacting the cancer cells with an inhibitor on NGly1, optionally in combination with a direct proteasome inhibitor.
Claims15
A method of treating cancer, the method comprising:
- contacting cancer cells with an Ngly1 inhibitor that does not inhibit caspase activity, wherein said Ngly1 inhibitor is in a dose effective to reduce expression of a cancer cell proteasome;
- and
- concomitant administration of a direct proteasome inhibitor in a dose effective to inhibit proteasome activity in the cancer cells, wherein the number of viable cancer cells is reduced.
A composition, comprising an Ngly1 inhibitor in a unit dose effective to reduce proteasome expression in a targeted cell;
- and a direct proteasome inhibitor in a unit dose effective to inhibit proteasome activity.
Dependencies are inferred from the claim text.